Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Short Communication

Breakthrough infections with the SARS-CoV-2 Delta variant: vaccinations halved transmission risk

L. Hsu a, b, *, J. Hurraß a, A. Kossow a, c, J. Klobucnik a, J. Nießena, G.A. Wiesmüllera, c, B. Grüne a, d, C. Joistena, d, e

a Public Health Department Cologne, Infektions- und Umwelt hygiene, Neumarkt 15-21, 50667 Cologne, Germany
b Institute for Occupational Medicine and Social Medicine, University Hospital, Medical Faculty, RWTH Aachen University, Aachen, Germany
c Institute of Hygiene, University Hospital Muenster, Albert-Schweitzer-Campus 1, 48149 Münster, Germany
d Department for Physical Activity in Public Health, Institute of Movement and Neurosciences, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50633 Cologne, Germany
e These authors contributed equally to this article.

* Corresponding author. Public Health Department Cologne, Infektions- und Umwelt hygiene, Neumarkt 15-21, 50667 Köln, Germany. Tel.: +4915779847123.
E-mail addresses: Lea.hsu@stadt-koeln.de, Lea.hsu@posteo.de (L. Hsu).

Available online 11 January 2022

© 2022 The Authors. Published by Elsevier Ltd on behalf of The Royal Society for Public Health. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

The SARS-CoV-2 Delta (B.1.617.2) variant of concern (VoC) has rapidly become the dominant variant in numerous countries and now accounts for more than 95% of cases in Germany.1 It was first reported in India in early October 2020 and increasingly displaced other SARS-CoV-2 variants, such as Alpha (B.1.1.7), Beta (B.1.351) and Gamma (P.1). In addition to other authors, Liu et al.2 identified the spike mutation P681R as a significant determinant for enhanced viral replication fitness of the Delta variant compared with the Alpha variant. Thus, the R0 (the initial reproduction number in an immune-naïve population) of the ancestral COVID-19 strain (wild type), the Alpha variant and the Delta variant were reported as 2.4—2.6, 4—5 and 5—8, respectively.3

Initial data show that (full) vaccination protects against infection with the Delta variant, but vaccine effectiveness seems to be reduced.4 However, it is unclear whether complete vaccination influences onward transmission in the case of so-called breakthrough infections. Preliminary results found no difference in viral load between unvaccinated and vaccinated individuals with breakthrough infections.5 In contrast, Chia et al. demonstrated that the viral load of B.1.617.2 decreased more rapidly in vaccinated than in unvaccinated infected individuals (preliminary data).6 In terms of breakthrough B.1.617.2 infections after AstraZeneca vaccination, Chau et al. described asymptomatic or mild diseases, which were associated with higher cycle threshold (Ct) values, prolonged polymerase chain reaction (PCR) positivity and low levels of vaccine-induced neutralising antibodies.7 However, the effect of vaccination...
is not only via neutralising antibodies but also cellular immunity. Thus, a robust T-cell response also correlates with clinical protection and is probably involved in immunity to COVID-19 even with a reduction in antibodies.\textsuperscript{5}

Accurate assessment of breakthrough infections and the risk of ongoing transmission from vaccinated infected individuals to other (vaccinated) persons is essential in successfully fighting this pandemic. So far, however, no corresponding studies on vaccine-induced protection in terms of the Delta variant are available. To date, methods analysing onward transmissions or transmission risks have been highly respectively. Ct values are frequently used as a marker of infectivity, resp. viral load. Other possibilities are monitoring, cohort studies or the tracking of close contacts according to the legal regulations for the control of infectious diseases, as has been done by the German Public Health Departments on the basis of the Infection Protection Act. Close contact individuals in Germany are defined as those who had contact with an infected person (IP) for >10 min at <1.5 m, without face masks or direct physical contact, within a timeframe ranging from 2 days before symptom onset in the IP to 10–14 days after symptom onset.\textsuperscript{6}

To analyse vaccine-induced protection in terms of Delta variant breakthrough infections, real-world data from the largest German public health department, which is based in Cologne, were used. Data for the transmission of B.1.617.2 infection to close contacts were compared between fully vaccinated IPs in the vaccination group (VG) and IPs in the unvaccinated control group (CG).

Methods

A total of 679 B.1617.2 infections were reported to the public health department in Cologne between 19 April (occurrence of the first B.1617.2 case) and 24 July 2021; 116 of these infections were in fully vaccinated individuals, defined as >14 days after receipt of all recommended COVID-19 vaccine doses. Of the 116 fully vaccinated individuals, 47 had been vaccinated with Pfizer BNT162b2 (55.3%), three had been vaccinated with Moderna mRNA-1273 (3.5%), six had been vaccinated with Astra Zeneca AZD1222 (7.1%), 24 had been vaccinated with Johnson & Johnson Ad26.COV2.S (28.2%) and 5 had been vaccinated with a combination vaccine (5.9%). The last vaccination took place on average 56.8 ± 40.2 days before infection, with a range of 16–176 days.

From the 116 fully vaccinated individuals, only patients for whom complete contact tracing was possible were included (n = 85 [VG]). Individuals for whom complete contact tracing was not possible or who were incompletely vaccinated were excluded.

We selected a control population (CG) from the Cologne Health Department’s registry. The CG included patients with PCR-confirmed COVID-19 during the same observation period who had not yet received any vaccination. Each patient in the VG was randomly matched 1:1 with a B.1617.2-positive patient without vaccination (CG). Age and sex were chosen as matching criteria, as they may influence immune response on vaccination and transmissibility.

Data analyses

We considered the total number of contacts per IP and the total number of infected contacts per IP to determine the infected contacts relative to the total number of contacts per IP. In addition to descriptive statistics (age and sex), differences between VG and CG were assessed using an unpaired t-test or a chi-squared test. Linear regression (backwards elimination) was used to examine the influence of vaccination (yes = 0, no = 1), age (in years), sex (male = 1, female = 2), symptoms (present = 1, not present = 2) and vaccination interval (in days) on the number of infected contacts relative to the total number of contacts per IP. A P value below 0.05 was considered significant. All calculations were performed with SPSS version 27.0.

Results

In both the VG and CG, 45.9% were female. On average, vaccinated individuals were aged 35.8 ± 17.7 years; this did not differ from the CG (age: 34.8 ± 16.0 years). In the VG group, 138 close contacts (range per IP 0–9) were identified, compared with 95 close contacts in the CG (range per IP 0–7). The number of total and infected contacts, as well as the number of infected contacts in relation to the total number of contacts per IP, are shown in Table 1. There was a trend towards a higher number of total contacts per IP in the VG, but these contacts were significantly less infected. The total number of infected contacts per IP and the number of infected contacts in relation to the total number of contacts per IP were higher in the unvaccinated CG. The number of infected contacts in relation to the total number of contacts per IP increased in the unvaccinated group (beta = 0.350; P < .001) and with age (beta = 0.454; P < .001). This model was able to explain 30.8% (corr. $R^2$) of the variance. Sex, symptoms and vaccination interval (in days) were excluded in the final model (see table S1 in the supplementary material).

Of the 138 close contacts in the VG, 80 (58.0%) were fully vaccinated, whereas only 23 (24.2%) of 95 close contacts in the CG were fully vaccinated (P < .001; see Table 1). Fully vaccinated

### Table 1

| Variable | Group (n) | Mean | Standard deviation | P-value* |
|----------|-----------|------|--------------------|----------|
| Number of contacts per IP\textsuperscript{a} | VG (85) | 1.62 | 1.85 | 0.056 |
| | CG (85) | 1.12 | 1.57 | 0.001 |
| Number of infected contacts per IP\textsuperscript{a} | VG (57) | 0.47 | 0.76 | 0.001 |
| | CG (42) | 1.17 | 1.23 | 0.001 |
| Number of infected contacts to total number of contacts per IP\textsuperscript{a} | VG (57) | 0.26 | 0.40 | 0.001 |
| | CG (42) | 0.56 | 0.45 | 0.001 |
| Number of fully vaccinated contacts per IP | VG (57) | 1.40 | 1.32 | <0.001 |
| | CG (42) | 0.55 | 0.92 | <0.001 |
| Number of infected, fully vaccinated contacts per IP | VG (42) | 0.38 | 0.62 | 0.270 |
| | CG (15) | 0.60 | 0.74 | 0.120 |
| Number of infected, fully vaccinated contacts in relation to total number of fully vaccinated contacts per IP | VG (38) | 0.29 | 0.43 | 0.360 |
| | CG (13) | 0.41 | 0.48 | 0.360 |

* Calculated with unpaired t-test.
\textsuperscript{a} Persons who did not indicate close contacts were also integrated in order not to distort the number.
\textsuperscript{b} Only taken into account if close contacts were indicated.
contacts in the VG had an infection rate of 20.0% (n = 16) compared with 37.5% (n = 9) in the CG. The total number of fully vaccinated contacts infected, and the total number of fully vaccinated contacts infected in relation to the total number of vaccinated contacts per IP did not differ significantly.

**Discussion**

Based on real-world studies, SARS-CoV-2 vaccines have reassuring safety and can effectively reduce fatal outcomes, severe cases, symptomatic cases and infections. In addition, a follow-up of 6 months after the application of BNT162b2 showed a favourable safety profile, but with a gradual decline in efficacy. However, few and inconsistent data exist regarding the transmission of the SARS-CoV-2 Delta variant between fully vaccinated individuals. Such knowledge is essential for the implementation of effective infection control measures. Most studies are currently looking at the occurrence of breakthrough infections and the clinical course. However, the results are very heterogeneous. Two studies reported substantially lower viral loads in BNT162b2-infected patients who were vaccinated compared with those who were not vaccinated. In contrast, Ioannou et al. showed comparable viral loads among vaccinated and non-vaccinated healthcare workers infected with variant B.1.1.7, suggesting suboptimal protection of SARS-CoV-2 vaccines against new variants compared with wild-type SARS-CoV-2.

Most studies focus on the risk of infection or infectivity, and little is known about the transmission risk of close contacts in terms of the SARS-CoV-2 Delta variant. Therefore, to our knowledge, this is the first study based on epidemiological data to investigate the ongoing transmission of B.1.617.2 from fully vaccinated IPs to close (vaccinated) contacts. The results of the present study show a significant reduction in transmission of more than 50% in vaccinated compared with unvaccinated IPs.

Similarly, fully vaccinated contacts were less likely to be infected by fully vaccinated IPs than by unvaccinated IPs (20.0% vs 37.5%), although this association was not significant.

**Strengths and limitations**

A strength of this study is the systematic and complete recording of the data by the Cologne Public Health Department. IPs were digitally recorded and interviewed via telephone to determine the route of infection, symptoms and medical history, including vaccination. In each case, VoC analysis was carried out via PCR, provided that sufficient sample material was available. Accordingly, the proportion of B.1.617.2 infections was complete compared with other surveys, which often assume estimated values. In addition, all close contacts in Cologne were also tracked during quarantine, both digitally and by telephone. PCR testing was carried out when symptoms occur.

This study is limited by its small number of IPs and fully vaccinated close contacts. In addition, deviations in PCR tests and sequencing in various Cologne laboratories are possible because a unified method is not present. Although the ct values were recorded, they were only available at one test time in IPs; therefore, ct values were not taken into account in the context of this analysis and among new variants.

**Conclusions**

In conclusion, fully vaccinated individuals who are infected with B.1.617.2 can transmit the infection to close contacts; however, they had a >50% reduced transmission rate compared with the unvaccinated CG. These findings must now be verified in larger sample populations. It will be especially important to investigate the role of vaccination status of close contacts and to also consider the decreased efficacy of the vaccine over time.

**Author statements**

**Acknowledgements**

The authors want to thank all members of the contact tracing team at the Cologne Public Health Department.

**Ethical approval**

None sought.

**Funding**

None declared.

**Competing interests**

None declared.

**Appendix A. Supplementary data**

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jpuhe.2022.01.005.

**References**

1. RKI - Coronavirus SARS-CoV-2 - Tabelle zum VOC-Bericht - Anzahl und Anteile von VOC und VOI in Deutschland. Rki.de. Available from: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Daten/VOC_VOI_Tabelle.html [accessed 2021 Aug 17].
2. Liu Y, Liu J, Johnson RA, Xia H, Ku Z, Schindewolf C, et al. Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant. bioRxiv [Preprint] 2021 Sep 5. 2021.08.12.456173.
3. Hendaus MA, Jonha FA. Delta variant of COVID-19: a simple explanation. Qatar Med J 2021;2021[3]:49.
4. Brown CM, Vostok J, Johnson H, Burns M, Gharpure R, Sami S, et al. Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine breakthrough infections, associated with large public gatherings - Barnstable County, Massachusetts, July 2021. MMWR Morb Mortal Wkly Rep 2021;70(31):1059–62.
5. Riemersma KK, Gregor BE, Kita-Yarbro A, Halfmann P, Kocharian A, Florek KR, et al. Shedding of infectious SARS-CoV-2 despite vaccination when the delta variant is prevalent - Wisconsin, July 2021. medRxiv 2021.11.20.21261387 [Preprint]. https://doi.org/10.1101/2021.11.20.21261387. 2021.07.31.22163187.
6. Chia PV, Xiang Ong SW, Chiew CJ, Ang LW, Chavatte J-M, Mak T-M, et al. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study [Internet]. bioRxiv. 2021. [accessed 2021 Jul 28]. bioRxiv 2021.07.28.21261295. Available from:.
7. Chau NVV, Ngoc NM, Quang VM, Ny NTH, Khia DB, et al. An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam. Clin Med 2021;41:101143.
8. Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat Rev Immunol 2021;21(8):473–84.
9. European Centre for Disease Prevention and Control. Guidance for discharge and ending isolation of people with COVID-19, 16 October 2020. Stockholm: ECDC; 2020. [Accessed 17 August 2021].
10. Liu Q, Qin C, Liu M, Liu J. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis. Infect Dis Poverty 2021;10:1:132.
11. Thomas SJ, Moreira Jr ED, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. C4591001 clinical trial group. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine through 6 months. N Engl J Med 2021;385(19):1761–73.
12. Levine-Tiefenbrun M, Kita-Yarbro A, Halfmann P, Kocharian A, Florek KR, et al. Shedding of infectious SARS-CoV-2 despite vaccination when the delta variant is prevalent - Wisconsin, July 2021. medRxiv 2021.11.20.21261387 [Preprint]. https://doi.org/10.1101/2021.11.20.21261387. 2021.07.31.22163187.
13. McElhinstem MC, Clancy CJ, Buehrle DJ, Lucas A, Decker BK. Single dose of a mRNA SARS-CoV-2 vaccine is associated with lower nasopharyngeal viral load among nursing home residents with asymptomatic COVID-19. Clin Infect Dis 2021;73(6):e1365–7.
14. Ioannou P, Karakonstantis S, Astrinaki E, Saplamidou S, Vitsaxaki E, Hamilos G, et al. Transmission of SARS-CoV-2 variant B.1.1.7 among vaccinated health care workers. Inf Dis (Lond) 2021;53(11):876–9.

L. Hsu, J. Hurraß, A. Kossow et al. Public Health 204 (2022) 40–42

42